NATIONAL ADAP MONITORING PROJECT - AIDS United

Chart 6
ADAP Drug Expenditures, by Class, June 2001
NNRTI
12%
“A1” OI
5%
Note: Connecticut, Guam, Maine, and Massachusetts not included.
OI/All Other
8%
Total = $63,789,458
20
PI
29%
NRTI
46%
In June 2001, fifty states, representing 98% of total ADAP drug expenditures, were able to provide expenditure
data for all drug classes, including the 16 “A1” opportunistic infection drugs recommended by the Infectious
Disease Society of America/Public Health Service. Spending breakdowns were similar to last year’s National
ADAP Monitoring Report. Antiretrovirals continue to account for the bulk of ADAP drug expenditures (87%).
Among the three classes of approved antiretroviral drugs—nucleoside reverse transcriptase inhibitors (NRTIs),
protease inhibitors (PIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs)—NRTIs account for almost
half of ADAP drug expenditures (46%), followed by PIs (29%), and NNRTIs (12%). All other drugs, including
drugs that prevent and treat opportunistic infections, account for 13% of drug spending. The 16 “A1” OI drugs
alone accounted for 5% spent of total drug spending (see Appendix II).
The 16 “A1” drugs as recommended by the Infectious Disease Society of American/Public Health Service,
Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus,
November 2001 include: acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin),
famciclovir (Famvir), fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH),
itraconazole (Sporonox), leucovorin, pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampin, sulfadiazine, and
TMP/SMX (Bactrim).